Global Hypertension in CKD Market, by Drug Class (Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 191.8 million in 2020 and is expected to exhibit a CAGR of 10.6% during the forecast period (2020-2027).
Increasing research and development activities by the key players is expected to drive the growth of the market over the forecast period. For instance, on December 7, 2020, KBP Biosciences Holdings Limited announced positive results from its Phase 2b clinical trial of its lead candidate, KBP-5074. KBP-5074 is a non-steroidal mineralocorticoid receptor antagonist (MRA), which is being developed to treat patients suffering from chronic kidney disease and uncontrolled hypertension.
According to the Nephropharmacology journal: 2019, the following table depicts the suggested first, second, and third-line drug choices for the treatment of hypertension in CKD:
|Prescribing Order||Drug Class|
|First||RAS Blockade (Angiotensin-converting-enzyme inhibitors (ACEI) or Angiotensin II receptor blockers (ARB))|
|Second||Calcium Channel Blockers|
Global Hypertension in CKD Market - Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic is expected to restrain growth of the global hypertension in CKD market over the forecast period. According to National Center for Biotechnology Information (NCBI), September 29, 2020, the treatment for chronic kidney diseases might be delayed due to the pandemic. Moreover, during the COVID-19 pandemic, the treatment of kidney disorders patients is postponed or even cancelled due to the unavailability of medications due to irregular supply and transportation of drugs.
Furthermore, according to the U.S Food and Drug Administration (FDA), September 18, 2020, the COVID-19 pandemic has disrupted the global drug supply due to government-mandated or recommended temporary shutdowns, safety initiatives to ensure employee health and well-being, insufficient labor force, and restrictions on import and export activities, and travel.
Browse 32 Market Data Tables and 25 Figures spread through 156 Pages and in-depth TOC on Global Hypertension in CKD Market, by Drug Class (Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the hypertension in CKD market, click the link below:
Increasing prevalence of chronic kidney disease (CKD) and diabetic kidney disease (DKD), among the age groups is expected to drive the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention, (CDC), March 4, 2021, in the U.S., approximately 15% of the U.S. adults or 37 million people are currently suffering from chronic kidney disease. The following graph shows the percentage of U.S. adults in different age groups (age 18 years and above), suffering from chronic kidney disease:
Moreover, according to the National Institute of Diabetes and Digestive and Kidney Diseases: 2020, high blood glucose can damage the blood vessels in the kidneys, as many people with diabetes also develop high blood pressure. This is called as diabetic kidney disease (DKD) in type 2 diabetes. According to National Center for Biotechnology Information, (NCBI): 2017, the prevalence of DKD in most type 2 diabetics, at any point in time, is approximately 30%-50% among the U.S. diabetic adults. This prevalence was ranging between 25% in patients younger than 65 years old to nearly 50% with age older than 65 years. Therefore, patients suffering from DKD are at higher chances of suffering from hypertension.
Key Takeaways of the Hypertension in CKD Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.